Anthony Lau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Anthony Lau has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Hans Haag
Faculty of Pharmaceutical Sciences University of British Columbia Vancouver British Columbia Canada
2 shared publications - Pouya Azar
Psychiatry, Vancouver General Hospital, Vancouver, CAN
2 shared publications - Yau-Lam Alex Chau
Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada
2 shared publications - Aaron M. Tejani
Lower Mainland Pharmacy Services (Fraser Health) and The University of British Columbia, Vancouver, British Columbia
1 shared publication - Alisha Hussey
Department of Emergency Medicine, University of British Columbia, Vancouver, Canada
1 shared publication - Andrew Kestler
Department of Emergency Medicine, University of British Columbia, Vancouver, Canada
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 41 (3) , 598-607
Esmolol in the management of refractory ventricular fibrillation: a systematic review and meta-analysis
Background: Refractory ventricular fibrillation (rVF) presents a significant challenge in advanced cardiovascular life support (ACLS), with traditional antiarrhythmics showing limited success in improving long-term survival and neurological function. Esmolol, a beta-1 selective adrenergic receptor antagonist, might offer benefits due to its rapid onset and catecholamine-suppressing effects during cardiac arrest.Methods: This systematic review and meta-analysis (SRMA) evaluates the effectiveness of esmolol in improving the temporary return of spontaneous circulation (ROSC), sustained ROSC, survival to discharge, and survival to discharge with favorable neurological outcomes in rVF patients. This SRMA reviewed Medline (Ovid), Embase (Ovid), and Cochrane Central (Ovid) from their inception until October 2, 2025, for full-text clinical or observational studies assessing esmolol use alongside standard ACLS in adult rVF in both prehospital and in-hospital settings.Results: The risk of bias was independently assessed using the Newcastle-Ottawa Scale. Pooled risk ratios (RRs; 95% CI) are reported. Analyses in which I² >50% used a random-effects model; otherwise, a common-effect model was used. Four studies (n=273) are included. Esmolol was associated with an increased temporary ROSC (RR, 1.80; 95% CI, 1.09–2.98), and although the links were not statistically significant, esmolol trended toward a benefit in sustained ROSC (RR, 1.25; 95% CI, 0.28–5.66), survival to discharge (RR, 1.08; 95% CI, 0.57–2.03), and survival to discharge with favorable neurological outcomes (RR, 2.08; 95% CI, 0.83–5.24).Conclusions: Esmolol was associated with improved temporary ROSC in rVF. The sensitivity analysis suggests potential benefits for sustained ROSC and neurological survival, but more data are needed. Further research is needed to clarify its role.
- 31 August 2026
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 41 (3) , 598-607
Open AccessEsmolol in the management of refractory ventricular fibrillation: a systematic review and meta-analysis
Background: Refractory ventricular fibrillation (rVF) presents a significant challenge in advanced cardiovascular life support (ACLS), with traditional antiarrhythmics showing limited success in improving long-term survival and neurological function. Esmolol, a beta-1 selective adrenergic receptor antagonist, might offer benefits due to its rapid onset and catecholamine-suppressing effects during cardiac arrest.Methods: This systematic review and meta-analysis (SRMA) evaluates the effectiveness of esmolol in improving the temporary return of spontaneous circulation (ROSC), sustained ROSC, survival to discharge, and survival to discharge with favorable neurological outcomes in rVF patients. This SRMA reviewed Medline (Ovid), Embase (Ovid), and Cochrane Central (Ovid) from their inception until October 2, 2025, for full-text clinical or observational studies assessing esmolol use alongside standard ACLS in adult rVF in both prehospital and in-hospital settings.Results: The risk of bias was independently assessed using the Newcastle-Ottawa Scale. Pooled risk ratios (RRs; 95% CI) are reported. Analyses in which I² >50% used a random-effects model; otherwise, a common-effect model was used. Four studies (n=273) are included. Esmolol was associated with an increased temporary ROSC (RR, 1.80; 95% CI, 1.09–2.98), and although the links were not statistically significant, esmolol trended toward a benefit in sustained ROSC (RR, 1.25; 95% CI, 0.28–5.66), survival to discharge (RR, 1.08; 95% CI, 0.57–2.03), and survival to discharge with favorable neurological outcomes (RR, 2.08; 95% CI, 0.83–5.24).Conclusions: Esmolol was associated with improved temporary ROSC in rVF. The sensitivity analysis suggests potential benefits for sustained ROSC and neurological survival, but more data are needed. Further research is needed to clarify its role.
- Open Access
- 31 March 2026
- Published by The Korean Society of Emergency Medicine in Clinical and Experimental Emergency Medicine
- Vol. 13 (1) , 13-27
The role of fomepizole in acetaminophen-related poisoning: a narrative review
N-acetylcysteine (NAC) as the gold standard antidote in cases of acetaminophen (APAP)-related poisoning might not be sufficient with delayed presentation or massive ingestion. Human reports up until July 2021 suggest that fomepizole could play a role in APAP overdoses by inhibiting cytochrome P450 2E1 (CYP2E1)-mediated N-acetyl-p-benzoquinone imine (NAPQI) production and JNK-mediated oxidative damage. This narrative review builds on previous systematic and scoping reviews by adding the latest evidence about the use of fomepizole in APAP poisoning to better understand the hepatoprotective role and safety profile of this medication, as well as its practical place in therapy. A systematic search of MEDLINE and Embase was completed through November 2024. Studies involving human patients with APAP toxicity who received fomepizole treatment were included. Each case was summarized in tables to identify clinical trends, particularly the risk of hepatotoxicity, quantity of ingestion, time of presentation since ingestion, therapeutic and dosing regimens, and clinical outcomes. This review covers 30 studies and 45 patients across 18 case reports and 6 case series. When used with NAC, fomepizole seemed to result in favorable laboratory and clinical outcomes in most patients at high risk of hepatotoxicity because of late presentation or massive APAP ingestion. The available data suggest that fomepizole might complement NAC in treating severe APAP toxicity. Though they lack detailed clinical outcome analyses, case studies suggest that fomepizole could improve hepatotoxicity, survival, and transplant-free days.
- 31 March 2026
- Published by The Korean Society of Emergency Medicine in Clinical and Experimental Emergency Medicine
- Vol. 13 (1) , 13-27
Open AccessThe role of fomepizole in acetaminophen-related poisoning: a narrative review
N-acetylcysteine (NAC) as the gold standard antidote in cases of acetaminophen (APAP)-related poisoning might not be sufficient with delayed presentation or massive ingestion. Human reports up until July 2021 suggest that fomepizole could play a role in APAP overdoses by inhibiting cytochrome P450 2E1 (CYP2E1)-mediated N-acetyl-p-benzoquinone imine (NAPQI) production and JNK-mediated oxidative damage. This narrative review builds on previous systematic and scoping reviews by adding the latest evidence about the use of fomepizole in APAP poisoning to better understand the hepatoprotective role and safety profile of this medication, as well as its practical place in therapy. A systematic search of MEDLINE and Embase was completed through November 2024. Studies involving human patients with APAP toxicity who received fomepizole treatment were included. Each case was summarized in tables to identify clinical trends, particularly the risk of hepatotoxicity, quantity of ingestion, time of presentation since ingestion, therapeutic and dosing regimens, and clinical outcomes. This review covers 30 studies and 45 patients across 18 case reports and 6 case series. When used with NAC, fomepizole seemed to result in favorable laboratory and clinical outcomes in most patients at high risk of hepatotoxicity because of late presentation or massive APAP ingestion. The available data suggest that fomepizole might complement NAC in treating severe APAP toxicity. Though they lack detailed clinical outcome analyses, case studies suggest that fomepizole could improve hepatotoxicity, survival, and transplant-free days.
- Open Access
- 27 March 2026
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 23, 100691
The efficacy and safety of short-acting, full agonist opioids for symptom management of opioid withdrawal
- 27 March 2026
- Published by Elsevier in Addictive Behaviors Reports
- Vol. 23, 100691
Open AccessThe efficacy and safety of short-acting, full agonist opioids for symptom management of opioid withdrawal
- Open Access
- 1 March 2026
- Published by Society of Emergency Medicine Pharmacists in Journal of Acute Care Pharmacotherapy
- Vol. 2 (1)
ActionADE - Connecting Care to Save Lives
Adverse drug events (ADEs) are a major source of preventable patient harm, yet limited interoperability among electronic medical records often leaves clinicians unaware of prior ADEs, increasing the risk of repeated incidents. ActionADE is an interoperable electronic ADE reporting platform that integrates with British Columbia’s PharmaNet database, providing real-time alerts linked to culprit medications to support clinical decision-making and prevent re-exposures. Real-world data demonstrate that ActionADE improves communication across care settings, enables pharmacists and physicians to intervene more effectively, and reduces repeat ADEs. Implementation lessons highlight the importance of workflow integration, local champions, and scalability for broader adoption. These findings suggest that ActionADE is a practical, pharmacist-driven intervention to improve medication safety and optimize outcomes in acute care environments.
- 1 March 2026
- Published by Society of Emergency Medicine Pharmacists in Journal of Acute Care Pharmacotherapy
- Vol. 2 (1)
Open AccessActionADE - Connecting Care to Save Lives
Adverse drug events (ADEs) are a major source of preventable patient harm, yet limited interoperability among electronic medical records often leaves clinicians unaware of prior ADEs, increasing the risk of repeated incidents. ActionADE is an interoperable electronic ADE reporting platform that integrates with British Columbia’s PharmaNet database, providing real-time alerts linked to culprit medications to support clinical decision-making and prevent re-exposures. Real-world data demonstrate that ActionADE improves communication across care settings, enables pharmacists and physicians to intervene more effectively, and reduces repeat ADEs. Implementation lessons highlight the importance of workflow integration, local champions, and scalability for broader adoption. These findings suggest that ActionADE is a practical, pharmacist-driven intervention to improve medication safety and optimize outcomes in acute care environments.
- 14 July 2025
- Published by Springer Nature in Canadian Journal of Emergency Medicine
- Vol. 27 (11) , 860-863
Just the facts: rivastigmine for the management of anticholinergic toxicity
- 14 July 2025
- Published by Springer Nature in Canadian Journal of Emergency Medicine
- Vol. 27 (11) , 860-863
Just the facts: rivastigmine for the management of anticholinergic toxicity
- Open Access
Clinical Outcomes of Pharmacist Involvement in Cardiac Arrest and Trauma Resuscitations: A Scoping Review
Background: The role of clinical pharmacists in the emergency department continues to gain recognition, particularly during cardiac and trauma resuscitations. However, their contributions to patient outcomes remain unclear. The objective of this scoping review with narrative synthesis was to determine the impact of pharmacists on medication and patient outcomes during cardiac and trauma resuscitations and to identify barriers to integration. Methods: A literature search of databases in September 2024 identified randomized and non-randomized control trials, evaluating the impact of pharmacists’ involvement in cardiac or trauma resuscitations. Excluded were studies on acute stroke, acute hemorrhage, and sepsis. Data were extracted and analyzed for primary (e.g., medication errors and Advanced Cardiovascular Life Support [ACLS] compliance) and secondary outcomes (e.g., pharmacists’ education and training). Results: Of the 560 records screened, 26 records were included in the final analysis. Due to heterogeneity, quantitative analysis was not feasible. Among primary outcomes, ACLS guideline compliance and medication errors were commonly reported; mortality and length of stay were less commonly reported. ACLS certification improved pharmacists’ confidence in their tasks. Pharmacists’ presence also correlated with reduced healthcare costs. Conclusions: Our analysis suggests that the involvement of pharmacists in the context of emergency cardiac or trauma resuscitations may benefit direct patient outcomes and indirect outcomes.
Open AccessClinical Outcomes of Pharmacist Involvement in Cardiac Arrest and Trauma Resuscitations: A Scoping Review
Background: The role of clinical pharmacists in the emergency department continues to gain recognition, particularly during cardiac and trauma resuscitations. However, their contributions to patient outcomes remain unclear. The objective of this scoping review with narrative synthesis was to determine the impact of pharmacists on medication and patient outcomes during cardiac and trauma resuscitations and to identify barriers to integration. Methods: A literature search of databases in September 2024 identified randomized and non-randomized control trials, evaluating the impact of pharmacists’ involvement in cardiac or trauma resuscitations. Excluded were studies on acute stroke, acute hemorrhage, and sepsis. Data were extracted and analyzed for primary (e.g., medication errors and Advanced Cardiovascular Life Support [ACLS] compliance) and secondary outcomes (e.g., pharmacists’ education and training). Results: Of the 560 records screened, 26 records were included in the final analysis. Due to heterogeneity, quantitative analysis was not feasible. Among primary outcomes, ACLS guideline compliance and medication errors were commonly reported; mortality and length of stay were less commonly reported. ACLS certification improved pharmacists’ confidence in their tasks. Pharmacists’ presence also correlated with reduced healthcare costs. Conclusions: Our analysis suggests that the involvement of pharmacists in the context of emergency cardiac or trauma resuscitations may benefit direct patient outcomes and indirect outcomes.
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative
Background: For patients with opioid use disorder, Sublocade (extended-release buprenorphine; Bup-XR-S) and Buvidal/Brixadi (long-acting buprenorphine; Bup-LA-B) formulations allow for less frequent dosing. Traditional induction with Bup-XR-S requires 7 or more days on transmucosal buprenorphine can delay care and increase disengagement risk. Quicker transition to Bup-XR-S or Bup-LA-B presents a promising strategy. With the prevalence of potent illicit opioids, stabilization within 7 days is critical to prevent overdose and withdrawal. This narrative review assesses outcomes of transitions to long-acting injectable buprenorphine within 7 days of the last sublingual dose. Methods: A systematic search of MEDLINE and EMBASE was completed through February 14, 2025. Studies involving patients with opioid use disorder who underwent Bup-XR-S and Bup-LA-B transition were included. Data on patient characteristics, buprenorphine dosing, retention rates, and outcomes were extracted and synthesized. Results: We identified 21 studies, totaling 534 patients, that met our inclusion criteria. For Bup-XR-S studies, 75 patients transitioned to Bup-XR-S within 24 hours. Of patients, 4% experienced withdrawal symptoms requiring additional opioid support. All Bup-LA-B studies reported transitions within 24 hours. Short-term retention (4 wk) exceeded 60%. Adverse events were infrequent and primarily mild, including injection site pain, nausea, and constipation. Conclusions: Limited descriptive studies suggest transitioning to Bup-XR-S within 7 days appears feasible, well-tolerated, and supports treatment adherence. Following labelled dosing, Bup-LA-B transitions within 24 hours were effective and well-tolerated. While these approaches may help initiate opioid agonist therapy in high-risk populations and mitigate overdose risks, further research is needed to confirm effectiveness and impact on retention.
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of Addiction Medicine
Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative
Background: For patients with opioid use disorder, Sublocade (extended-release buprenorphine; Bup-XR-S) and Buvidal/Brixadi (long-acting buprenorphine; Bup-LA-B) formulations allow for less frequent dosing. Traditional induction with Bup-XR-S requires 7 or more days on transmucosal buprenorphine can delay care and increase disengagement risk. Quicker transition to Bup-XR-S or Bup-LA-B presents a promising strategy. With the prevalence of potent illicit opioids, stabilization within 7 days is critical to prevent overdose and withdrawal. This narrative review assesses outcomes of transitions to long-acting injectable buprenorphine within 7 days of the last sublingual dose. Methods: A systematic search of MEDLINE and EMBASE was completed through February 14, 2025. Studies involving patients with opioid use disorder who underwent Bup-XR-S and Bup-LA-B transition were included. Data on patient characteristics, buprenorphine dosing, retention rates, and outcomes were extracted and synthesized. Results: We identified 21 studies, totaling 534 patients, that met our inclusion criteria. For Bup-XR-S studies, 75 patients transitioned to Bup-XR-S within 24 hours. Of patients, 4% experienced withdrawal symptoms requiring additional opioid support. All Bup-LA-B studies reported transitions within 24 hours. Short-term retention (4 wk) exceeded 60%. Adverse events were infrequent and primarily mild, including injection site pain, nausea, and constipation. Conclusions: Limited descriptive studies suggest transitioning to Bup-XR-S within 7 days appears feasible, well-tolerated, and supports treatment adherence. Following labelled dosing, Bup-LA-B transitions within 24 hours were effective and well-tolerated. While these approaches may help initiate opioid agonist therapy in high-risk populations and mitigate overdose risks, further research is needed to confirm effectiveness and impact on retention.
- Open Access
- 17 December 2024
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e70167
Developing a SNOMED CT-based value set to document symptoms and diagnoses for adverse drug events: A mixed-methods study (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Adverse drug events (ADE) lead to over two million emergency department visits in Canada annually, resulting in significant patient harm and over $1 billion in healthcare costs. Effective documentation and sharing of ADE information through electronic medical records (EMRs) is essential to inform subsequent care and improve safety when culprit medications can be replaced and re-exposures avoided. Yet current systems often lack standardized comprehensive ADE value sets. Objective: This study aimed to develop a SNOMED CT value set for symptoms and diagnoses to standardize ADE documentation and improve ADE data integration into EMRs. Methods: We used ADE data from ActionADE, a prospective reporting system implemented in nine hospitals in British Columbia. We extracted 5,792 reports that yielded 827 unique ADE symptom and diagnosis terms based on MedDRA preferred terms. Two independent mappers employed both automated and manual mapping approaches to match these terms to SNOMED CT concepts. Two clinical experts conducted validation, followed by a quality assurance review by a separate clinical team. Discrepancies were resolved through consensus discussions. Interrater reliability was assessed using Cohen’s kappa. Results: The automated mapping process identified 63.8% (528/827) semantically equivalent matches from SNOMED CT’s Clinical Finding hierarchy. Two mappers manually reviewed the automatically mapped terms and identified appropriate target concepts for the unmapped terms. After the manual mapping process, 95.3% (788/827) of the source terms were successfully mapped to SNOMED CT concepts, with 4.7% (39/827) remaining unmapped. Interrater reliability between the mappers was strong (κ = 0.87, 95% CI: 0.85-0.89). The validation phase identified and removed one irrelevant term, resulting in 98.9% (778/826) terms mapped, with 1.6% (9/826) unmapped, and a high interrater reliability (κ = 0.88, 95% CI: 0.80-0.95). During quality assurance, six terms were flagged for concerns regarding clinical relevance or safety risks and were resolved through discussions. The final value set comprised 813 SNOMED CT concepts, with 95.0% of terms classified as semantically equivalent. Thirteen additional terms remained unmapped and will be reviewed as new SNOMED CT codes are added. Conclusions: This study developed a SNOMED CT-based value set to document symptoms and diagnoses for adverse drug events observed in adults in EMRs. Adopting this value set can improve the consistency, accuracy, and interoperability of ADE documentation in EMRs, helping to reduce repeat ADEs and enhance patient safety. Ongoing refinement and improved clinical usability are essential for its widespread adoption. Future research should assess the impact of integrating this value set into EMRs on ADE reporting, pharmacovigilance, and patient safety outcomes.
- 17 December 2024
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13, e70167
Open AccessDeveloping a SNOMED CT-based value set to document symptoms and diagnoses for adverse drug events: A mixed-methods study (Preprint)
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Adverse drug events (ADE) lead to over two million emergency department visits in Canada annually, resulting in significant patient harm and over $1 billion in healthcare costs. Effective documentation and sharing of ADE information through electronic medical records (EMRs) is essential to inform subsequent care and improve safety when culprit medications can be replaced and re-exposures avoided. Yet current systems often lack standardized comprehensive ADE value sets. Objective: This study aimed to develop a SNOMED CT value set for symptoms and diagnoses to standardize ADE documentation and improve ADE data integration into EMRs. Methods: We used ADE data from ActionADE, a prospective reporting system implemented in nine hospitals in British Columbia. We extracted 5,792 reports that yielded 827 unique ADE symptom and diagnosis terms based on MedDRA preferred terms. Two independent mappers employed both automated and manual mapping approaches to match these terms to SNOMED CT concepts. Two clinical experts conducted validation, followed by a quality assurance review by a separate clinical team. Discrepancies were resolved through consensus discussions. Interrater reliability was assessed using Cohen’s kappa. Results: The automated mapping process identified 63.8% (528/827) semantically equivalent matches from SNOMED CT’s Clinical Finding hierarchy. Two mappers manually reviewed the automatically mapped terms and identified appropriate target concepts for the unmapped terms. After the manual mapping process, 95.3% (788/827) of the source terms were successfully mapped to SNOMED CT concepts, with 4.7% (39/827) remaining unmapped. Interrater reliability between the mappers was strong (κ = 0.87, 95% CI: 0.85-0.89). The validation phase identified and removed one irrelevant term, resulting in 98.9% (778/826) terms mapped, with 1.6% (9/826) unmapped, and a high interrater reliability (κ = 0.88, 95% CI: 0.80-0.95). During quality assurance, six terms were flagged for concerns regarding clinical relevance or safety risks and were resolved through discussions. The final value set comprised 813 SNOMED CT concepts, with 95.0% of terms classified as semantically equivalent. Thirteen additional terms remained unmapped and will be reviewed as new SNOMED CT codes are added. Conclusions: This study developed a SNOMED CT-based value set to document symptoms and diagnoses for adverse drug events observed in adults in EMRs. Adopting this value set can improve the consistency, accuracy, and interoperability of ADE documentation in EMRs, helping to reduce repeat ADEs and enhance patient safety. Ongoing refinement and improved clinical usability are essential for its widespread adoption. Future research should assess the impact of integrating this value set into EMRs on ADE reporting, pharmacovigilance, and patient safety outcomes.
- Open Access
- 6 May 2024
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (9) , 1173-1180
A Simulation‐Based Assessment of Levetiracetam Concentrations Following Fixed and Weight‐Based Loading Doses: A Meta‐Regression and Pharmacokinetic Modeling Analysis
Current recommendations for refractory status epilepticus (SE) unresponsive to benzodiazepines suggest a loading dose of levetiracetam (LEV) of 60 mg/kg to a maximum of 4500 mg. LEV therapeutic drug monitoring can help guide therapy and is garnering increasing attention. The objective of this study is to simulate the probability of target attainment (PTA) of fixed dose and weight-based loading doses of LEV with respect to established therapeutic target concentrations. Meta-regression of the current literature was performed to evaluate the relationship between intravenous LEV loading dose and seizure cessation in refractory SE patients. A previously published pharmacokinetic model was used to simulate the PTA capacity of competing single intravenous dosing schemes (fixed vs weight-based dosing) to achieve maximum (C-peak) and 12-h (C-12h) plasma concentrations that exceed 12 mg/L. The meta-regression indicated that dosage was not a statistically significant modulator of seizure control at dosages between 20 and 60 mg/kg. Stochastic simulations showed all dosing schemes achieved plasma C-peak >12 mg/L, but C-12h levels were <12 mg/L in subjects over 60 kg with a fixed dose <= 2000 mg or in subjects <60 kg with a weight-based dose = 90% PTAs across all weights. Using a weight-based loading dose of 40 mg/kg, up to a suggested maximum of 4500 mg, improves the likelihood of achieving a sustained therapeutic drug concentration after the initial LEV dose, whereas fixed <3000 mg may not achieve the desired concentration before maintenance dosing.
- 6 May 2024
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 64 (9) , 1173-1180
Open AccessA Simulation‐Based Assessment of Levetiracetam Concentrations Following Fixed and Weight‐Based Loading Doses: A Meta‐Regression and Pharmacokinetic Modeling Analysis
Current recommendations for refractory status epilepticus (SE) unresponsive to benzodiazepines suggest a loading dose of levetiracetam (LEV) of 60 mg/kg to a maximum of 4500 mg. LEV therapeutic drug monitoring can help guide therapy and is garnering increasing attention. The objective of this study is to simulate the probability of target attainment (PTA) of fixed dose and weight-based loading doses of LEV with respect to established therapeutic target concentrations. Meta-regression of the current literature was performed to evaluate the relationship between intravenous LEV loading dose and seizure cessation in refractory SE patients. A previously published pharmacokinetic model was used to simulate the PTA capacity of competing single intravenous dosing schemes (fixed vs weight-based dosing) to achieve maximum (C-peak) and 12-h (C-12h) plasma concentrations that exceed 12 mg/L. The meta-regression indicated that dosage was not a statistically significant modulator of seizure control at dosages between 20 and 60 mg/kg. Stochastic simulations showed all dosing schemes achieved plasma C-peak >12 mg/L, but C-12h levels were <12 mg/L in subjects over 60 kg with a fixed dose <= 2000 mg or in subjects <60 kg with a weight-based dose = 90% PTAs across all weights. Using a weight-based loading dose of 40 mg/kg, up to a suggested maximum of 4500 mg, improves the likelihood of achieving a sustained therapeutic drug concentration after the initial LEV dose, whereas fixed <3000 mg may not achieve the desired concentration before maintenance dosing.